Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | APLT |
---|---|---|
09:32 ET | 17157 | 8.42 |
09:34 ET | 6559 | 8.335 |
09:36 ET | 100 | 8.4 |
09:38 ET | 1900 | 8.415 |
09:39 ET | 2672 | 8.43 |
09:41 ET | 105584 | 8.41 |
09:43 ET | 35669 | 8.57 |
09:45 ET | 15383 | 8.74 |
09:48 ET | 41886 | 8.79 |
09:50 ET | 25298 | 8.73 |
09:52 ET | 26312 | 8.715 |
09:54 ET | 7157 | 8.6357 |
09:56 ET | 4390 | 8.57 |
09:57 ET | 3699 | 8.595 |
09:59 ET | 790 | 8.56 |
10:01 ET | 300 | 8.575 |
10:03 ET | 12123 | 8.575 |
10:06 ET | 2058 | 8.475 |
10:08 ET | 3680 | 8.44 |
10:10 ET | 3064 | 8.45 |
10:12 ET | 6064 | 8.36 |
10:14 ET | 300 | 8.37 |
10:15 ET | 5428 | 8.32 |
10:17 ET | 1980 | 8.37 |
10:19 ET | 827 | 8.33 |
10:21 ET | 2160 | 8.34 |
10:24 ET | 8674 | 8.3401 |
10:26 ET | 4098 | 8.375 |
10:28 ET | 500 | 8.41 |
10:30 ET | 600 | 8.41 |
10:32 ET | 108645 | 8.46 |
10:33 ET | 3302 | 8.415 |
10:35 ET | 5253 | 8.53 |
10:37 ET | 7196 | 8.565 |
10:39 ET | 700 | 8.54 |
10:42 ET | 686 | 8.55 |
10:44 ET | 950 | 8.565 |
10:46 ET | 2768 | 8.5 |
10:48 ET | 200 | 8.5086 |
10:50 ET | 535 | 8.4801 |
10:53 ET | 1154 | 8.47 |
10:55 ET | 2300 | 8.45 |
10:57 ET | 2911 | 8.45 |
11:00 ET | 300 | 8.43 |
11:02 ET | 1318 | 8.43 |
11:04 ET | 800 | 8.435 |
11:06 ET | 1850 | 8.46 |
11:08 ET | 4519 | 8.51 |
11:09 ET | 1221 | 8.49 |
11:11 ET | 1572 | 8.485 |
11:13 ET | 3600 | 8.49 |
11:15 ET | 3258 | 8.51 |
11:18 ET | 200 | 8.51 |
11:20 ET | 1167 | 8.51 |
11:22 ET | 400 | 8.51 |
11:24 ET | 1100 | 8.5166 |
11:26 ET | 300 | 8.51 |
11:27 ET | 1700 | 8.47 |
11:29 ET | 3070 | 8.46 |
11:31 ET | 8428 | 8.51 |
11:33 ET | 800 | 8.535 |
11:36 ET | 6526 | 8.5397 |
11:38 ET | 500 | 8.51 |
11:40 ET | 3071 | 8.485 |
11:42 ET | 3230 | 8.43 |
11:44 ET | 717 | 8.4 |
11:45 ET | 500 | 8.4 |
11:47 ET | 700 | 8.4 |
11:49 ET | 200 | 8.4 |
11:51 ET | 1019 | 8.395 |
11:54 ET | 400 | 8.39 |
11:56 ET | 1490 | 8.38 |
11:58 ET | 1735 | 8.39 |
12:00 ET | 100 | 8.39 |
12:02 ET | 300 | 8.4 |
12:03 ET | 2950 | 8.36 |
12:05 ET | 1472 | 8.36 |
12:07 ET | 3807 | 8.33 |
12:09 ET | 1000 | 8.32 |
12:12 ET | 450 | 8.33 |
12:14 ET | 1523 | 8.36 |
12:16 ET | 400 | 8.35 |
12:18 ET | 820 | 8.36 |
12:20 ET | 2541 | 8.36 |
12:21 ET | 1081 | 8.37 |
12:23 ET | 3162 | 8.36 |
12:25 ET | 823 | 8.36 |
12:27 ET | 1079 | 8.38 |
12:30 ET | 337 | 8.39 |
12:32 ET | 100 | 8.39 |
12:34 ET | 1158 | 8.38 |
12:36 ET | 100 | 8.39 |
12:38 ET | 329 | 8.39 |
12:39 ET | 600 | 8.38 |
12:41 ET | 941 | 8.37 |
12:48 ET | 7900 | 8.39 |
12:50 ET | 3169 | 8.39 |
12:52 ET | 2965 | 8.38 |
12:54 ET | 1100 | 8.38 |
12:56 ET | 2351 | 8.385 |
12:57 ET | 1100 | 8.4 |
12:59 ET | 100 | 8.4 |
01:01 ET | 6004 | 8.35 |
01:03 ET | 2788 | 8.35 |
01:06 ET | 2639 | 8.38 |
01:08 ET | 3800 | 8.37 |
01:10 ET | 300 | 8.39 |
01:12 ET | 2699 | 8.37 |
01:14 ET | 1604 | 8.39 |
01:15 ET | 1100 | 8.38 |
01:17 ET | 1195 | 8.39 |
01:19 ET | 1300 | 8.37 |
01:21 ET | 1250 | 8.361 |
01:24 ET | 1800 | 8.38 |
01:26 ET | 1200 | 8.39 |
01:28 ET | 844 | 8.38 |
01:30 ET | 1819 | 8.35 |
01:32 ET | 12031 | 8.3 |
01:33 ET | 2052 | 8.26 |
01:35 ET | 6359 | 8.31 |
01:37 ET | 1125 | 8.31 |
01:39 ET | 1917 | 8.32 |
01:44 ET | 700 | 8.31 |
01:46 ET | 817 | 8.31 |
01:48 ET | 504 | 8.31 |
01:50 ET | 834 | 8.31 |
01:51 ET | 200 | 8.31 |
01:53 ET | 1173 | 8.31 |
01:55 ET | 200 | 8.31 |
01:57 ET | 1200 | 8.3 |
02:00 ET | 1166 | 8.32 |
02:02 ET | 663 | 8.34 |
02:04 ET | 4992 | 8.325 |
02:06 ET | 3182 | 8.33 |
02:08 ET | 2682 | 8.31 |
02:09 ET | 2785 | 8.31 |
02:11 ET | 100 | 8.32 |
02:13 ET | 2812 | 8.27 |
02:15 ET | 2929 | 8.26 |
02:18 ET | 2700 | 8.28 |
02:20 ET | 5603 | 8.24 |
02:22 ET | 2280 | 8.23 |
02:24 ET | 2843 | 8.22 |
02:26 ET | 2550 | 8.22 |
02:27 ET | 1000 | 8.21 |
02:29 ET | 1726 | 8.22 |
02:31 ET | 900 | 8.21 |
02:33 ET | 1010 | 8.21 |
02:36 ET | 3203 | 8.19 |
02:38 ET | 3605 | 8.24 |
02:40 ET | 2300 | 8.24 |
02:42 ET | 1607 | 8.27 |
02:44 ET | 2417 | 8.25 |
02:45 ET | 900 | 8.265 |
02:47 ET | 800 | 8.27 |
02:49 ET | 908 | 8.28 |
02:51 ET | 1100 | 8.25 |
02:54 ET | 1300 | 8.25 |
02:56 ET | 1500 | 8.26 |
02:58 ET | 6450 | 8.24 |
03:00 ET | 13497 | 8.235 |
03:02 ET | 12087 | 8.28 |
03:03 ET | 2295 | 8.24 |
03:05 ET | 13916 | 8.19 |
03:07 ET | 53116 | 8.23 |
03:09 ET | 4896 | 8.26 |
03:12 ET | 900 | 8.28 |
03:14 ET | 6993 | 8.31 |
03:16 ET | 3693 | 8.34 |
03:18 ET | 700 | 8.34 |
03:20 ET | 3500 | 8.35 |
03:21 ET | 300 | 8.36 |
03:23 ET | 41129 | 8.41 |
03:25 ET | 8158 | 8.44 |
03:27 ET | 1310 | 8.435 |
03:30 ET | 6359 | 8.41 |
03:32 ET | 2315 | 8.4 |
03:34 ET | 21353 | 8.42 |
03:36 ET | 8401 | 8.36 |
03:38 ET | 2600 | 8.365 |
03:39 ET | 5677 | 8.35 |
03:41 ET | 1500 | 8.36 |
03:43 ET | 1000 | 8.365 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Applied Therapeutics Inc | 561.6M | -5.5x | --- |
Iteos Therapeutics Inc | 609.9M | -3.4x | --- |
Q32 Bio Inc | 556.6M | -2.8x | --- |
Altimmune Inc | 560.0M | -3.8x | --- |
Eliem Therapeutics Inc | 567.3M | -2.4x | --- |
Third Harmonic Bio Inc | 555.7M | -16.2x | --- |
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $561.6M |
---|---|
Revenue (TTM) | $-333.0K |
Shares Outstanding | 114.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.04 |
EPS | $-1.52 |
Book Value | $-0.20 |
P/E Ratio | -5.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.